Cervical cancer: paclitaxel-carboplatin-bevacizumab shows efficacy in phase 2

  • Suzuki K & al.
  • Gynecol Oncol
  • 5 Jul 2019

  • curated by Deepa Koli
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • The combination of paclitaxel, carboplatin, and bevacizumab is feasible and well-tolerated in patients with advanced or recurrent cervical cancer.

Why this matters

  • This is the first study to report the efficacy of paclitaxel, carboplatin, and bevacizumab in patients with cervical cancer.

Study design

  • Phase 2 study of 34 patients (median age, 53 years) with advanced or recurrent cervical cancer who received a combination of paclitaxel, carboplatin, and bevacizumab every 21 days.
  • Funding: None.

Key results

  • Patients received a total of 260 treatment cycles (median, 6 cycles/patient).
  • Median follow-up, 18.5 months.
  • Objective response rate was 88% (95% CI, 72.5%-96.7%), and median duration of response was 6 months.
  • Rate of complete response was 50% (95% CI, 32.4%-67.6%), partial response was 38% (95% CI, 22.2%-56.4%), and stable disease was 9% (95% CI, 1.9%-23.7%).
  • Median PFS was 9 (95% CI, 6.7-11.5) months, and OS was 26 (95% CI, 14.3-37.7) months. 
  • Grade 3/4 hematologic adverse event rate: neutropenia (41.2%), leukopenia (41.2%), anemia (32.4%), and thrombocytopenia (26.5%).
  • 1 episode of grade 3 bronchopulmonary hemorrhage and 1 grade 2 rectovaginal fistula was reported.

Limitations

  • Small number of patients.
  • Limited generalizability.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit